EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects

Mohamad Bakkar iD, Sara Khalil, Komal Bhayekar, Narva Deshwar Kushwaha, Amirreza Samarbakhsh, Sadaf Dorandish, Holly Edwards, Q Ping Dou iD, Yubin Ge iD, Navnath S Gavande iD

Biomolecules · 07.02.2025 · 15 (2) · 240

DOI: 10.3390/biom15020240 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 07.02.2025. Verfasst von Mohamad Bakkar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS), Wayne State University, Detroit, MI 48201, …. Hauptthemen laut MEDLINE: Neoplasms, Ubiquitin-Specific Proteases, Protease Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer management has traditionally depended on chemotherapy as the mainstay of treatment; however, recent advancements in targeted therapies and immunotherapies have offered new options. Ubiquitin-specific proteases (USPs) have emerged as promising therapeutic targets in cancer treatment due to their crucial roles in regulating protein homeostasis and various essential cellular processes. This review covers the following: (1) the structural and functional characteristics of USPs, highlighting their involvement in key cancer-related pathways, and (2) the discovery, chemical structures, mechanisms of action, and potential clinical implications of USP inhibitors in cancer therapy. Particular attention is given to the role of USP inhibitors in enhancing cancer immunotherapy, e.g., modulation of the tumor microenvironment, effect on regulatory T cell function, and influence on immune checkpoint pathways. Furthermore, this review summarizes the current progress and challenges of clinical trials involving USP inhibitors as cancer therapy. We also discuss the complexities of achieving target selectivity, the ongoing efforts to develop more specific and potent USP inhibitors, and the potential of USP inhibitors to overcome drug resistance and synergize with existing cancer treatments. We finally provide a perspective on future directions in targeting USPs, including the potential for personalized medicine based on specific gene mutations, underscoring their significant potential for enhancing cancer treatment. By elucidating their mechanisms of action, clinical progress, and potential future applications, we hope that this review could serve as a useful resource for both basic scientists and clinicians in the field of cancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsUbiquitin-Specific ProteasesProtease InhibitorsAntineoplastic AgentsHumansTumor MicroenvironmentAnimals

Stichwörter der Autor:innen

cancer therapydeubiquitinating enzymes (DUBs)small molecule inhibitorsubiquitin-specific proteases (USPs)

Substanzen

Ubiquitin-Specific ProteasesProtease InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS), Wayne State University, Detroit, MI 48201, USA.
  • Division of Pediatric Hematology and Oncology, Children's Hospital of Michigan, Detroit, MI 48201, USA.
  • Cancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI 48201, USA.
  • Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA.
  • Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute (KCI), Wayne State University School of Medicine, Detroit, MI 48201, USA.

ORCID-Profile: Mohamad Bakkar, Q Ping Dou, Yubin Ge, Navnath S Gavande

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health
  • Department of Defense
  • VA, KCI’s Michigan SPORE, Richard Barber Interdisciplinary Research Program
  • DMC Foundation
  • WSU Applebaum Faculty Research Award (FRAP)

Zitieren

APA

Bakkar, M., Khalil, S., Bhayekar, K., Kushwaha, N. D., Samarbakhsh, A., Dorandish, S., Edwards, H., Dou, Q. P., Ge, Y., & Gavande, N. S. (2025). Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects. Biomolecules, 15(2), 240. https://doi.org/10.3390/biom15020240

Vancouver

Bakkar M, Khalil S, Bhayekar K, Kushwaha ND, Samarbakhsh A, Dorandish S, et al. Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects. Biomolecules. 2025;15(2):240. doi:10.3390/biom15020240

BibTeX
@article{Bakkar2025,
  author = {Bakkar, Mohamad and Khalil, Sara and Bhayekar, Komal and Kushwaha, Narva Deshwar and Samarbakhsh, Amirreza and Dorandish, Sadaf and Edwards, Holly and Dou, Q Ping and Ge, Yubin and Gavande, Navnath S},
  title = {Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects},
  journal = {Biomolecules},
  year = {2025},
  volume = {15},
  number = {2},
  pages = {240},
  doi = {10.3390/biom15020240}
}
Kostenlos starten →